Evidence map›Paper›PMID 38457402›Full record

ArticlePloS one2024

Photoimmuno-antimicrobial therapy for Staphylococcus aureus implant infection.

Bruce van Dijk, Sabrina Oliveira, J Fred F Hooning van Duyvenbode, F Ruben H A Nurmohamed, Vida Mashayekhi, Irati Beltrán Hernández, Jos van Strijp, Lisanne de Vor, Piet C Aerts, H Charles Vogely and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Bruce van DijkDepartment of Orthopedics, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0009-0005-8501-8115
Sabrina OliveiraDepartment of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.
J Fred F Hooning van DuyvenbodeDepartment of Orthopedics, University Medical Center Utrecht, Utrecht, The Netherlands.
F Ruben H A NurmohamedDepartment of Orthopedics, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0001-5369-9853
Vida MashayekhiDepartment of Biology, Faculty of Science, Utrecht University, Utrecht, The Netherlands.
Irati Beltrán HernándezDepartment of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.
Jos van StrijpDepartment of Medical Microbiology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Lisanne de VorDepartment of Medical Microbiology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Piet C AertsDepartment of Medical Microbiology, University Medical Centre Utrecht, Utrecht, The Netherlands.
H Charles VogelyDepartment of Orthopedics, University Medical Center Utrecht, Utrecht, The Netherlands.
Harrie WeinansDepartment of Orthopedics, University Medical Center Utrecht, Utrecht, The Netherlands.
Bart C H van der WalDepartment of Orthopedics, University Medical Center Utrecht, Utrecht, The Netherlands.
University Medical Center Utrecht · NLUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionImplant infections caused by Staphylococcus aureus are responsible for high mortality and morbidity worldwide. Treatment of these infections can be difficult especially when bacterial biofilms are involved. In this study we investigate the potential of infrared photoimmunotherapy to eradicate staphylococcal infection in a mouse model.

methodsA monoclonal antibody that targets Wall Teichoic Acid surface components of both S. aureus and its biofilm (4497-IgG1) was conjugated to a photosensitizer (IRDye700DX) and used as photoimmunotherapy in vitro and in vivo in mice with a subcutaneous implant pre-colonized with biofilm of Staphylococcus aureus. A dose of 400 μg and 200 μg of antibody-photosensitizer conjugate 4497-IgG-IRDye700DXwas administered intravenously to two groups of 5 mice. In addition, multiple control groups (vancomycin treated, unconjugated IRDye700DX and IRDye700DX conjugated to a non-specific antibody) were used to verify anti-microbial effects.

resultsIn vitro results of 4497-IgG-IRDye700DX on pre-colonized (biofilm) implants showed significant (p<0.01) colony-forming units (CFU) reduction at a concentration of 5 μg of the antibody-photosensitizer conjugate. In vivo, treatment with 4497-IgG-IRDye700DX showed no significant CFU reduction at the implant infection. However, tissue around the implant did show a significant CFU reduction with 400 μg 4497-IgG-IRDye700DX compared to control groups (p = 0.037).

conclusionThis study demonstrated the antimicrobial potential of photoimmunotherapy for selectively eliminating S. aureus in vivo. However, using a solid implant instead of a catheter could result in an increased bactericidal effect of 4497-IgG-IRDye700DX and administration locally around an implant (per operative) could become valuable applications in patients that are difficult to treat with conventional methods. We conclude that photoimmunotherapy could be a potential additional therapy in the treatment of implant related infections, but requires further improvement.

Indexed as

Staphylococcal InfectionsStaphylococcus aureusAnimalsAnti-Bacterial AgentsBiofilmsHumansImmunoglobulin GMicePhotosensitizing AgentsAnti-Bacterial AgentsImmunoglobulin GPhotosensitizing Agents

Identifiers

PMID38457402
PMCPMC10923484
OpenAlexW4392582531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.